Application of vitamin B3 in preparation of anti-hepatoma drugs
By using vitamin B3 alone or in combination with PD-L1 blocking antibody or lenvatinib in liver cancer treatment, the problem of low response rate in patients with advanced liver cancer is solved, significantly inhibiting the progression of liver cancer, improving the treatment effect, and achieving early stage of liver cancer Precise and individual intervention in prevention and control.
Patent Information
- Application Number
- CN202411200509.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-29
AI Technical Summary
The existing liver cancer treatment plan has low response rate to patients with advanced liver cancer, and the high heterogeneity of liver cancer leads to poor targeted treatment results. The lack of effective biomarkers and targeted intervention strategies makes it difficult to achieve the precise prevention and treatment of liver cancer in the early stage. and individualized intervention.
By using vitamin B3 alone or in combination with PD-L1 blocking antibody or lenvatinib, the infiltration abundance of CD8+ T cells and M1-type tumor-associated macrophages in the microenvironment of liver cancer tumors was significantly improved, and G-MDSCs were inhibited and G-MDSCs were inhibited. M2 tumor-associated macrophages remodel the anti-tumor immune microenvironment and enhance the effect of lenvatinib or PDL1 antibody treatment.
Significantly reduce the risk of liver cancer and death, delay the progress trend of liver cancer, significantly inhibit the progress of liver cancer tumors, improve the effect of liver cancer treatment, and enhance the effect of immune combination and targeted therapy. Vitamin B3 is safer as a natural ingredient, avoiding Toxic side effects of drug treatment.
Smart Images

Figure CN119033783A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of anti-tumor technology, and in particular to an application of vitamin B3 in the preparation of an anti-liver cancer drug. Background Art
[0002] The occurrence and development of liver cancer is mostly the result of imbalance in liver microenvironment homeostasis caused by the long-term interaction of multiple factors such as genetic susceptibility, dietary imbalance and unhealthy lifestyle. With the changes in modern lifestyle and dietary structure, it is easy to cause nutritional imbalance in the human body. At the same time, the most unique advantage of nutrition in medical practice is to move the window of chronic disease prevention and control forward. Therefore, nutritional intervention plays an irreplaceable role in the prevention, control and treatment of liver cancer.
[0003] Clinical treatment strategies for liver cancer include surgical treatment, ablation therapy, transarterial chemoembolization, radiotherapy and systemic therapy (molecular targeted drugs, immunotherapy and chemotherapy). Although liver resection or liver transplantation is the most effective treatment for patients with early liver cancer, it is not suitable for the clinical treatment of patients with advanced liver cancer. According to the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)" issued by the National Health Commission, targeted drugs approved for the first-line treatment of liver cancer patients include atezolizumab combined with bevacizumab, sintilimab combined with bevacizumab analogs, donafenib, lenvatinib, sorafenib and FOLFOX4 regimen. Although the current first-line treatment strategy has achieved certain results in the treatment of liver cancer patients, due to the high heterogeneity of liver cancer, a considerable number of patients do not respond to or have a low response rate to the current treatment regimen. Therefore, the prevention and treatment of liver cancer is still a difficult problem that needs to be overcome urgently. We still need to explore new biomarkers related to the occurrence, development and treatment of liver cancer and their targeted intervention strategies, so as to predict the tumor progression process of liver cancer patients in clinical practice, and ultimately achieve precise and individualized intervention in the early prevention and treatment of liver cancer.
[0004] Liver cancer is a dynamic ecological system, in which heterogeneous tumor cells interact with immune cells, stromal cells, and endothelial cells to form a complex tumor microenvironment. The tumor microenvironment of liver cancer is usually in an immunosuppressive inflammatory state. On the one hand, it assists tumor cells in immune escape and promotes the malignant progression of liver cancer, but on the other hand, it also makes liver cancer one of the solid tumor types suitable for immunotherapy. In recent years, with the discovery of a variety of immune checkpoints, immunotherapy has brought great hope for humans to conquer cancer, so targeting various immune cells in the microenvironment to reshape the anti-tumor immune microenvironment has gradually become a hot topic in the development of new strategies for liver cancer treatment. Among them, myeloid cells, as immune cells that specifically express CD11b molecules, are the most important cell type in the immune microenvironment of liver cancer. Myeloid cells infiltrating the liver cancer tumor microenvironment usually include bone marrow-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). Specifically, MDSCs can be divided into multinuclear MDSCs (G-MDSCs) and mononuclear MDSCs (M-MDSCs), and TAMs can be divided into anti-tumor M1-like TAMs and pro-tumor M2-like TAMs according to their functional status. Hepatocellular carcinoma cells promote their own progression by recruiting myeloid cells and training them to polarize toward an immunosuppressive state. The trained immunosuppressive myeloid cells are characterized by high expression of anti-inflammatory factors (such as VEGF, IL-10, and Arg-1) and self-recruitment of related chemokines (such as CCL2, CSF-1, CXCL1, CXCL2, and CXCL5), which inhibit the tumor killing function of CD8+T lymphocytes in the tumor microenvironment. Therefore, myeloid cells play an important role in the formation of an immunosuppressive microenvironment in liver cancer, which is usually closely related to the malignant progression and poor prognosis of liver cancer.
[0005] As the core metabolic organ of the human body, the liver plays an important role in the metabolism and absorption of vitamin B3. Vitamin B3 is widely found in animal liver and kidney, milk, eggs, bran and fresh vegetables. The human body can obtain it from food or through additional dietary supplements. Currently, research on vitamin B3 mainly focuses on the cardiovascular field.
[0006] In the development of liver cancer, recognized genetic changes include mutations in tumor suppressor genes TP53 (NCBI Gene ID: 7157) and PTEN (NCBI Gene ID: 5728) and overexpression of the MYC oncogene (NCBI Gene ID: 4609).
[0007] Prior patent CN114099508 A discloses the use of vitamins in anti-tumor drugs and anti-tumor drugs, which are mainly targeted at Ras tumors. RAS mutations are common in pancreatic cancer, non-small cell lung cancer and colorectal cancer, but not common in liver cancer. In addition, the dosage (10-30mmol / L) described in the patent cannot be actually converted into an in vivo dosage. Summary of the invention
[0008] In view of this, the purpose of the present invention is to provide an application of vitamin B3 in the preparation of anti-liver cancer drugs. The present invention first discovered that vitamin B3 can significantly increase the infiltration abundance of CD8+T cells and M1 tumor-associated macrophages in the liver cancer tumor microenvironment, and significantly inhibit the content of G-MDSCs and M2 tumor-associated macrophages; vitamin B3 can significantly inhibit the progression of liver cancer, has the effect of reshaping the anti-tumor immune microenvironment, and has the effect of sensitizing lenvatinib or PDL1 antibody to treat liver cancer.
[0009] The objective of the present invention is achieved through the following technical solutions:
[0010] <First aspect>
[0011] The present invention provides an application of vitamin B3 in preparing an anti-liver cancer drug.
[0012] The application is the use of vitamin B3 alone; or the combined use of vitamin B3 and PD-L1 blocking antibody; or the combined use of vitamin B3 and lenvatinib.
[0013] When the vitamin B3 is used alone, the dosage of the vitamin B3 is 50-100 mg / kg / d, and the number of days of use is 20-180 days.
[0014] When vitamin B3 and PD-L1 blocking antibody are used in combination, the dosage of vitamin B3 is 50-100 mg / kg / d; the number of days of use is 20-30 days; the dosage of PD-L1 blocking antibody is 5-10 mg / kg, the number of times of use is 2-4 times, and the interval between each time is 3-4 days;
[0015] When vitamin B3 and lenvatinib are used in combination, the dosage of vitamin B3 is 50-100 mg / kg / d, and the number of days of use is 20-30 days; the dosage of lenvatinib is 10-15 mg / kg / d, and the number of days of use is 15-20 days.
[0016] The PD-L1 blocking antibody includes one of nivolumab, pembrolizumab, durvalumab, toripalizumab, carrelizumab, sintilimab, tislelizumab, InVivoMAb anti-mouse PD-L1 (B7-H1), etc.
[0017] <Second Aspect>
[0018] An anti-tumor pharmaceutical composition, wherein the active ingredients of the pharmaceutical composition include vitamin B3 and PD-L1 blocking antibodies.
[0019] The dosage of vitamin B3 is 50-100 mg / kg / d; the usage period is 20-30 days; the dosage of PD-L1 blocking antibody is 5-10 mg / kg, the usage is 2-4 times, and the interval between each time is 3-4 days.
[0020] The PD-L1 blocking antibody includes one of nivolumab, pembrolizumab, durvalumab, toripalizumab, carrelizumab, sintilimab, tislelizumab, InVivoMAb anti-mouse PD-L1 (B7-H1), etc.
[0021] The use of the above-mentioned pharmaceutical composition in the preparation of anti-liver cancer drugs also falls within the protection scope of the present invention.
[0022] <Third Aspect>
[0023] An anti-tumor pharmaceutical composition, wherein the active ingredients of the pharmaceutical composition include vitamin B3 and lenvatinib.
[0024] The dosage of vitamin B3 is 50-100 mg / kg / d, and the usage period is 20-30 days; the dosage of lenvatinib is 10-15 mg / kg / d, and the usage period is 15-20 days.
[0025] The use of the above-mentioned pharmaceutical composition in the preparation of anti-liver cancer drugs also falls within the protection scope of the present invention.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] 1. The present invention can effectively prevent and treat liver cancer by supplementing the active ingredient - vitamin B3 in the diet, including significantly reducing the risk of liver cancer and the risk of death, significantly inhibiting the progression of liver cancer, and having the effect of reshaping the anti-tumor immune microenvironment, while sensitizing the effect of lenvatinib or PDL1 antibody in treating liver cancer.
[0028] 2. The present invention found in the study that in the Hepa1-6 subcutaneous liver cancer model group and the DEN+CCl4-induced primary liver cancer model group, compared with the control, vitamin B3 intervention treatment significantly increased the infiltration abundance of CD8+T cells and M1 tumor-associated macrophages in the liver cancer tumor microenvironment, and significantly inhibited the content of G-MDSCs and M2 tumor-associated macrophages.
[0029] 3. In the study on vitamin B3-immunotherapy, it was found that compared with the control group (PD-L1 blocking antibody treatment alone), the vitamin B3-immunotherapy group (vitamin B3 combined with PD-L1 blocking antibody) had better anti-tumor effects, including delaying the progression of liver cancer and tumor weight at the experimental endpoint.
[0030] 4. In the vitamin B3-targeted combination therapy study, it was found that compared with the control group (lenvatinib alone), the vitamin B3-targeted therapy group (vitamin B3 combined with lenvatinib) had better anti-tumor effects, including delaying the progression of liver cancer and the tumor weight at the experimental endpoint.
[0031] Vitamin B3 is a natural component found in animal liver and kidney, milk, eggs, bran and fresh vegetables. From the perspective of clinical application, it is safer than other drugs for preventing and treating liver cancer. The vitamin B3 of the present invention can be added in the form of a dietary supplement to overcome the toxic and side effects caused by drug treatment, and the application will not be affected by the safety of vitamin B3. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0033] Figure 1 The figure is a diagram showing the effect of vitamin B3 in preventing and treating liver cancer in Example 1; wherein A is the change trend of tumor volume in mice of Hepa1-6 subcutaneous liver cancer model; B is the change trend of tumor weight in mice of Hepa1-6 subcutaneous liver cancer model; C is a representative liver picture of mice in DEN+CCl4 primary liver cancer model; D is the occurrence of liver tumor number in mice of DEN+CCl4 primary liver cancer model; E is the change of liver weight in mice of DEN+CCl4 primary liver cancer model.
[0034] Figure 2 This is a diagram showing the effect of vitamin B3 on regulating the immune microenvironment of liver cancer; A is the Hepa1-6 subcutaneous liver cancer model group; B is the DEN+CCl4-induced primary liver cancer model group;
[0035] Figure 3These are the effect diagrams of vitamin B3-targeted combined therapy and vitamin B3-immunotherapy against liver cancer in Example 2; wherein, A is the trend of tumor volume changes in mice after vitamin B3-immunotherapy in the Hepa1-6 subcutaneous liver cancer model; B is the trend of tumor weight changes in mice after vitamin B3-immunotherapy in the Hepa1-6 subcutaneous liver cancer model; C is the trend of tumor volume changes in mice after vitamin B3-targeted combined therapy in the Hepa1-6 subcutaneous liver cancer model; D is the trend of tumor weight changes in mice after vitamin B3-targeted combined therapy in the Hepa1-6 subcutaneous liver cancer model. DETAILED DESCRIPTION
[0036] The present invention is described in detail below in conjunction with embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. It should be noted that, for those of ordinary skill in the art, some adjustments and improvements can also be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.
[0037] In the following examples:
[0038] The tumor was measured with a vernier caliper according to the formula 1 / 2a×b 2 Calculate the volume, where a is the major diameter and b is the minor diameter.
[0039] Example 1 Effect of Vitamin B3 in the Prevention and Treatment of Liver Cancer
[0040] 1. Experimental Animals
[0041] Clean grade C57BL / 6 mice (male, 2 or 4 weeks old) were purchased from Shanghai Slake Company, and the mice were cultured in a pathogen-free biological breeding room under standard conditions. The use rules and experimental procedures of mice were approved by the Animal Ethics Committee of the Experimental Animal Center of Shanghai Jiao Tong University School of Medicine, and they were kept in Shanghai Jiao Tong University School of Medicine.
[0042] 2. Modeling and processing methods
[0043] 2.1. Hepa1-6 subcutaneous liver cancer model
[0044] 2×10 6 Hepa1-6 cells (diluted in 100 μL of DMEM medium containing 40% matrix and without fetal bovine serum) were injected into the left groin of C57BL / 6 mice to establish a subcutaneous liver cancer model. The occurrence and development of the tumor were recorded. Starting from the third day after tumor cell implantation, the tumor size was measured every 3 days for a period of 15 days. A Hepa1-6-induced subcutaneous liver cancer mouse model was constructed; the mice were randomly divided into control group A and vitamin B3 prevention and treatment group A.
[0045] Among them, the recipient mice in the vitamin B3 prevention and treatment group A were treated with different doses of vitamin B3 7 days before tumor implantation (vitamin B3 prevention and treatment group A-1 group 50 mg / kg / d, vitamin B3 prevention and treatment group A-2 group 100 mg / kg / d, gavage) until the end of the experiment.
[0046] 2.2. DEN+CCl4-induced primary liver cancer model
[0047] Two-week-old male C57BL / 6 mice were intraperitoneally injected with diethylnitrosamine (DEN, 25 mg / kg) to construct a mouse model of primary liver cancer, and the mice were randomly divided into control group B and vitamin B3 intervention treatment group B. At 3 weeks of age, mice in control group B and vitamin B3 intervention treatment group B were intraperitoneally injected with carbon tetrachloride (CCl4, 1 mL / kg, dissolved in olive oil) once a week until the end of the experiment. When the mice were 6 weeks old, 50 mg / kg / d of vitamin B3 was added to the drinking water of mice in vitamin B3 intervention treatment group A until the end of the experiment. The experimental period was about 5-6 months.
[0048] 3. Detection of tumor immune microenvironment in liver cancer
[0049] 3.1. Collect tumor tissue and blood samples from mice in control group A, vitamin B3 prevention group A-1, vitamin B3 prevention group A-2, control group B, and vitamin B3 intervention group B. After cutting with ophthalmic scissors, use the mouse tumor tissue dissociation kit from Miltenyi Biotec to dissociate the mouse tumor tissue into a single cell suspension.
[0050] 3.2. Use the red blood cell lysis solution (containing NH4Cl, KHCO3 and Na2EDTA) of Biyuntian Company to remove the red blood cells in the single cell suspension. Specifically: add 3 times the volume of the cell to the red blood cell lysis solution to the single cell suspension, gently blow to mix, and lyse for 1-2 minutes. Then centrifuge at 400-500g for 5 minutes and discard the supernatant. Resuspend the precipitate with PBS, continue to centrifuge at 500g for 3 minutes, and discard the supernatant. Repeat once, and wash twice in total.
[0051] 3.3. Resuspend the single cell suspension treated in step 3.2 with PBS and add 1x10 7The single cell suspension was incubated with anti-mouse CD16 / 32 antibody (1:50) at room temperature for 15 minutes to prevent non-specific binding of flow cytometry antibodies. After centrifugation of the incubation solution, the supernatant was discarded and the precipitate was retained. After the precipitate was washed with PBS, the single cell suspension was resuspended in PBS and then incubated with Fixable Viability Stain 510 dye (780 dye can also be used) at room temperature in the dark for 30 minutes to distinguish the cell viability in the single cell suspension. Then, the staining was terminated with PBS, and the cells were washed twice with PBS, resuspended with 200uL PBS, and finally incubated with relevant flow cytometry antibodies (Mouse CD45 FITC, Mouse CD3eBV421, MouseCD8αBV785, Mouse Ly6G PE-Cy7, Mouse CD11b PE, Mouse F4 / 80BV421, Mouse CD206 APC) for 1 hour in a 4-degree cold storage away from light, then washed twice with PBS, resuspended with at least 200uL PBS, and then tested on the machine.
[0052] The flow cytometer model is BD's FACS Aria III. Based on isotype control and fluorescence-minus-one (FMO) strategy, the gating strategies for various immune cells are as follows:
[0053] CD8+T cells (Live+CD45+CD3e+CD8+);
[0054] M1 tumor-associated macrophages (Live+CD45+Ly6G-CD11b+F4 / 80+CD206-);
[0055] M2 tumor-associated macrophages (Live+CD45+Ly6G-CD11b+F4 / 80+CD206+);
[0056] G-MDSC(Live+CD45+CD11b+Ly6G+).
[0057] 4. Detection of the effect of vitamin B3 in preventing and treating liver cancer
[0058] 4.1 Hepa1-6 subcutaneous liver cancer model (such as Figure 1 A and B)
[0059] Control group A: subcutaneous liver cancer in mice grew significantly, and the tumor weight increased significantly at the end point of the experiment;
[0060] Vitamin B3 prevention and treatment group: 50mg / kg / d (vitamin B3 prevention and treatment group A-1 group) or 100mg / kg / d (vitamin B3 prevention and treatment group A-2 group) can significantly alleviate the progression trend of liver cancer, and the weight of liver cancer tumors at the end point of the experiment was significantly inhibited.
[0061] 4.2DEN+CCl4-induced primary liver cancer model (such as Figure 1 C, D and E)
[0062] Control group B: All mice developed primary liver cancer, and the number and weight of tumors increased significantly at the end point of the experiment.
[0063] Vitamin B3 intervention treatment group B: 50 mg / kg / d significantly alleviated the occurrence and development of in situ liver cancer, and the number and weight of liver cancer tumors were significantly inhibited at the endpoint of the experiment.
[0064] 4.2 Effect of vitamin B3 on regulating the immune microenvironment of liver cancer
[0065] In the Hepa1-6 subcutaneous liver cancer model group (such as Figure 2 A) and DEN+CCl4-induced primary liver cancer model group ( Figure 2 In (B), compared with control group A, vitamin B3 intervention treatment (vitamin B3 prevention and treatment group A-1 group, vitamin B3 prevention and treatment group A-2 group) significantly increased the infiltration abundance of CD8+T cells and M1 tumor-associated macrophages in the tumor microenvironment of liver cancer, and significantly inhibited the content of G-MDSCs and M2 tumor-associated macrophages.
[0066] Example 2 Effects of Vitamin B3-targeted combined therapy and Vitamin B3-immune combined therapy against liver cancer
[0067] 1. Experimental Animals
[0068] Clean grade C57BL / 6 mice (male, 4 weeks old) were purchased from Shanghai Slake Company, and the mice were cultured in a pathogen-free biological breeding room under standard conditions. The use rules and experimental procedures of mice were approved by the Animal Ethics Committee of the Experimental Animal Center of Shanghai Jiao Tong University School of Medicine, and they were kept in Shanghai Jiao Tong University School of Medicine.
[0069] 2. Modeling and treatment methods (Hepa1-6 subcutaneous liver cancer model)
[0070] 2.1. Vitamin B3-immunotherapy
[0071] 2×10 6Hepa1-6 cells (diluted in 100 μL of DMEM medium containing 40% matrix and without fetal bovine serum) were injected into the left groin of C57BL / 6 mice to establish a subcutaneous liver cancer model. The occurrence and development of the tumor were recorded. Starting from the third day after tumor cell implantation, the tumor size was measured every 3 days for a period of 15 days. A Hepa1-6-induced primary liver cancer mouse model was constructed; the mice were divided into control group C and vitamin B3-immunotherapy combined treatment group.
[0072] In the vitamin B3-immunotherapy group, the recipient mice were treated with vitamin B3 (50 mg / kg / d, gavage) 7 days before Hepa1-6 tumor implantation until the end of the experiment; 100 μg (about 5 mg / kg) of PD-L1 blocking antibody was given on the 3rd, 6th and 9th days after Hepa1-6 tumor implantation.
[0073] Control group C was treated with 100 μg of PD-L1 blocking antibody (BioXcell, catalog number: BE0101) on days 3, 6, and 9 after Hepa1-6 tumor implantation.
[0074] 2.2 Vitamin B3-targeted combination therapy
[0075] 2×10 6 Hepa1-6 cells (diluted in 100 μL of DMEM medium containing 40% matrix and without fetal bovine serum) were injected into the left groin of C57BL / 6 mice to establish a subcutaneous liver cancer model. The occurrence and development of the tumor were recorded. Starting from the third day after tumor cell implantation, the tumor size was measured every 3 days for a period of 15 days. A Hepa1-6-induced primary liver cancer mouse model was constructed; the mice were divided into a control group D and a vitamin B3-targeted combined treatment group.
[0076] Vitamin B3-targeted therapy group: recipient mice were treated with vitamin B3 (50 mg / kg / d, gavage) 7 days before Hepa1-6 tumor implantation until the end of the experiment; on the 3rd day after Hepa1-6 tumor implantation, they were treated with 10 mg / kg / d of lenvatinib.
[0077] Control group D: 10 mg / kg / d of lenvatinib alone was administered on day 3 after Hepa1-6 tumor implantation.
[0078] 3. Results
[0079] 3.1 Vitamin B3-immunotherapy (eg Figure 3 A and B)
[0080] Compared with the control group C (PD-L1 blocking antibody treatment alone), the vitamin B3-immunotherapy group (vitamin B3 combined with PD-L1 blocking antibody) had the best anti-tumor effect, including delaying the progression of liver cancer and tumor weight at the experimental endpoint.
[0081] 3.2 Efficacy of vitamin B3 sensitization targeted therapy (such as Figure 3 C and D)
[0082] Compared with the control group D (lenvatinib alone), the vitamin B3-targeted therapy group (vitamin B3 combined with lenvatinib) had the best anti-tumor effect, including delaying the progression of liver cancer and the tumor weight at the experimental endpoint.
[0083] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art may make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.
Claims
1. Application of vitamin B3 in the preparation of anti-liver cancer drugs.
2. The use according to claim 1, characterized in that: The application is the use of vitamin B3 alone; or the combined use of vitamin B3 and PD-L1 blocking antibody; or the combined use of vitamin B3 and lenvatinib.
3. The use according to claim 2, characterized in that: The PD-L1 blocking antibody includes one of nivolumab, pembrolizumab, durvalumab, toripalimab, carrelizumab, sintilimab, tilelizumab, and InVivoMAb anti-mouse PD-L1.
4. An anti-tumor drug composition, characterized in that: The active ingredients of the pharmaceutical composition include vitamin B3 and PD-L1 blocking antibody.
5. The anti-tumor pharmaceutical composition according to claim 4, characterized in that: The dosage of vitamin B3 is 50-100 mg / kg / d; the usage period is 20-30 days; the dosage of PD-L1 blocking antibody is 5-10 mg / kg, the usage is 2-4 times, and the interval between each time is 3-4 days.
6. The antitumor pharmaceutical composition according to claim 4, characterized in that: The PD-L1 blocking antibody includes one of nivolumab, pembrolizumab, durvalumab, toripalimab, carrelizumab, sintilimab, tilelizumab, and InVivoMAb anti-mouse PD-L1.
7. Use of the pharmaceutical composition according to any one of claims 4 to 6 in the preparation of anti-liver cancer drugs.
8. An anti-tumor drug composition, characterized in that: The active ingredients of the pharmaceutical composition include vitamin B3 and lenvatinib.
9. The antitumor pharmaceutical composition according to claim 8, characterized in that: The dosage of vitamin B3 is 50-100 mg / kg / d, and the usage period is 20-30 days; the dosage of lenvatinib is 10-15 mg / kg / d, and the usage period is 15-20 days.
10. Use of the pharmaceutical composition according to any one of claims 8 or 9 in the preparation of anti-liver cancer drugs.
Citation Information
Patent Citations
Application of vitamin in anti-tumor medicine and anti-tumor medicine
CN114099508A
